Share that You are Attending an NCCN Event
Share that you are attending an NCCN event on your social media and encourage your colleagues to register for the event.
Share that you are attending an NCCN event on your social media and encourage your colleagues to register for the event.
Tafasitamab achieved a real-world overall response rate of 73.5%, with a median duration of response of 9.6 months.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve…
Peter Voorhees, MD; Noopur Raje, MD; Saad Z. Usmani, MD, MBA, FACP, FASCO
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve…
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the…
Online resource for healthcare professionals, providing information, news & support relating to multiple myeloma
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve…